{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:53:50Z","timestamp":1791568430555,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T00:00:00Z","timestamp":1470182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate the role of reported daily dose, age and other risk factors, and to assess the value of quantifying serum transaminase activity and paracetamol (acetaminophen) concentration at initial assessment for identifying patients at risk of hepatotoxicity following repeated supratherapeutic paracetamol ingestion (RSPI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Systematic literature review with collation and analysis of individual\u2010level data from reported cases of RSPI associated with liver damage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 199 cases meeting the selection criteria, severe liver damage (ALT\/AST \u22651000\u00a0IU\u00a0l<jats:sup>\u22121<\/jats:sup>, liver failure or death) was reported in 186 (93%) cases including 77\/78 (99%) children aged \u22646 years. Liver failure occurred in 127 (64%) cases; of these 49 (39%) died. Maximum ingested daily paracetamol doses were above UK recommendations in 143 (72%) patients. US\u2013Australasian thresholds for repeated supratherapeutic ingestions requiring intervention were not met in 71 (36%) cases; of these 35 (49%) developed liver failure and 10 (14%) died. No cases developing liver damage had paracetamol concentration &lt; 20\u00a0mg\u00a0l<jats:sup>\u22121<\/jats:sup> and a normal ALT\/AST on initial presentation or when RSPI was first suspected, but both of these values were only available for 79 (40%) cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Severe liver damage is reported after RSPI in adults and children, sometimes involving reported doses below current thresholds for intervention. Paracetamol concentrations &lt;20\u00a0mg\u00a0l<jats:sup>\u22121<\/jats:sup> with normal serum ALT\/AST activity on initial assessment suggests a low risk of subsequent liver damage. These findings are, however, limited by low patient numbers, publication bias and the accuracy of the histories in reported cases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13028","type":"journal-article","created":{"date-parts":[[2016,6,4]],"date-time":"2016-06-04T20:04:57Z","timestamp":1465070697000},"page":"923-931","source":"Crossref","is-referenced-by-count":24,"title":["Determinants of hepatotoxicity after repeated supratherapeutic paracetamol ingestion: systematic review of reported cases"],"prefix":"10.1111","volume":"82","author":[{"given":"Paul","family":"Acheampong","sequence":"first","affiliation":[{"name":"National Poisons Information Service, Newcastle Unit Newcastle upon Tyne Hospitals NHS Foundation Trust  Newcastle upon Tyne NE2 4HH UK"},{"name":"Royal Liverpool and Broadgreen University Hospitals NHS Trust  Liverpool L7 8XP UK"},{"name":"University of Liverpool Department of Pharmacology, Institute of Translational Medicine  Liverpool L69 3BX UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon H. L.","family":"Thomas","sequence":"additional","affiliation":[{"name":"National Poisons Information Service, Newcastle Unit Newcastle upon Tyne Hospitals NHS Foundation Trust  Newcastle upon Tyne NE2 4HH UK"},{"name":"Medical Toxicology Centre, Institute of Cellular Medicine, Wolfson Unit Newcastle University  Newcastle NE2 4HH UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04539.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520130063034"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520360043037"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.9.1219"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X219715"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04067.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0580-9"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/08035250600580503"},{"key":"e_1_2_7_10_1","first-page":"S256","article-title":"Hepatotoxicity in association with acetaminophen poisonings in the US","volume":"20","author":"Ahmad SR","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20948"},{"key":"e_1_2_7_12_1","unstructured":"National Poisons Information Service Report 2013\/14. Available athttp:\/\/www.npis.org\/NPISAnnualReport2013\u201014.pdf(last accessed 4 July 2016)."},{"key":"e_1_2_7_13_1","unstructured":"Toxbase Management of Therapeutic Excess of Paracetamol 2014. Available athttp:\/\/www.toxbase.org\/Chemicals\/Management\u2010Pages\/Paracetamol\u2010Index\u2010UK\/#therapeuticexcess(last accessed 2 March 2016)."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1102927"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6809.1026"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812153192401"},{"key":"e_1_2_7_17_1","first-page":"A1","article-title":"Paracetamol overdose: new guidance on treatment with intravenous acetylcysteine","volume":"6","year":"2012","journal-title":"Drug Safety Update"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6198.1097"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650500394571"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2008.tb01625.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220312"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2007.tb00943.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c6764"},{"key":"e_1_2_7_24_1","unstructured":"Royal College of Paediatrics and Child Health UK Growth Chart for Girls 2nd Edition January 2013. Available athttp:\/\/www.rcpch.ac.uk\/system\/files\/protected\/page\/NEW%20Girls%202\u201018yrs(4TH%20JAN%202012).pdf(last accessed 3 March 2016)."},{"key":"e_1_2_7_25_1","unstructured":"Royal College of Paediatrics and Child Health UK Growth Chart for Boys 2nd Edition January 2013. Available athttp:\/\/www.rcpch.ac.uk\/system\/files\/protected\/page\/NEW%20Boys%202\u201018yrs%20(4TH%20JAN%202013).pdf(last accessed 3 March 2016."},{"key":"e_1_2_7_26_1","volume-title":"WHO Child Growth Standards: Length\/height\u2010for\u2010age, weight\u2010for\u2010age, weight\u2010for\u2010length, weight\u2010for\u2010height and body mass index\u2010for\u2010age: methods and development","author":"WHO Multicentre Growth Reference Study Group","year":"2006"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.635149"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2012.746424"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2013.863906"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2014.987397"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2004.05.005"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.554839"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13028","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:56:25Z","timestamp":1696301785000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,3]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/bcp.13028"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13028","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,3]]}}}